{"627656":{"#nid":"627656","#data":{"type":"news","title":"Technologies Selected for Biolocity Commercialization Funding","body":[{"value":"\u003Cp\u003EFaculty at Georgia Tech, Emory University, and Georgia State University have been selected to receive a broad range of support from Biolocity to accelerate the commercialization of their patient impacting technologies. During their funding period, each team will receive project management and work directly with business experts and consultants to de-risk their technology and advance its development.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EBiolocity awardees are selected from in an intensive, multi-staged application process that includes market assessment, competitive analysis, and identification of development risks to be addressed for commercial success. All projects are selected by an oversight committee comprised of venture capitalists, entrepreneurs, clinicians, biomedical engineers and university technology transfer experts who make the difficult decision of identifying projects with the most compelling commercial potential.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EBelow are the innovative projects and teams selected for this year\u0026rsquo;s cohort.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E1.\u0026nbsp;\u003Cstrong\u003E\u003Ca href=\u0022http:\/\/emoryott.technologypublisher.com\/tech\/Novel_Bone_Forming_Compound_for_Use_in_Spinal_Fusion_Device\u0022\u003E12X Bone Regeneration for Spinal Fusion\u003C\/a\u003E\u003C\/strong\u003E: a repurposed, generic small molecule that induces bone formation to improve spinal fusion and prevent non-union.\u003Cbr \/\u003E\r\nPrincipal Investigators: Nick Willett, PhD, Emory University, Scott Boden, MD, Emory University, Sreedhara Sangadala, PhD, Emory University\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E2.\u0026nbsp;\u003Cstrong\u003E\u003Ca href=\u0022https:\/\/biolocity.gatech.edu\/wp-content\/uploads\/sites\/966\/2019\/09\/Heteroresistance-AST-Exec-Summary.pdf\u0022\u003EHeteroresistance AST\u003C\/a\u003E\u003C\/strong\u003E: an approach to determine antibiotic susceptibility, resistance, and hetero resistance within two hours of blood culture.\u003Cbr \/\u003E\r\nPrincipal Investigators: David Weiss, PhD, Emory University and Peter Yunker, PhD Georgia Tech\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E3.\u0026nbsp;\u003Cstrong\u003E\u003Ca href=\u0022http:\/\/emoryott.technologypublisher.com\/tech\/Biomarker_for_Clinical_Prognosis_for_Lung_Cancer_Patients\u0022\u003ESaGA for Cancer Drug Discovery\u003C\/a\u003E\u003C\/strong\u003E: a proprietary drug discovery platform utilizing a novel isolation assay for metastatic \u0026ldquo;leader\u0026rdquo; cells in solid tumors to develop novel cancer therapeutics.\u003Cbr \/\u003E\r\nPrincipal Investigator: Adam Marcus, PhD, Emory University\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E4.\u0026nbsp;\u003Cstrong\u003E\u003Ca href=\u0022https:\/\/biolocity.gatech.edu\/wp-content\/uploads\/sites\/966\/2019\/09\/20190902_Executive-Summary-SIRPant-.pdf\u0022\u003ESirpant Cellular Immunotherapy for Solid Tumors\u003C\/a\u003E\u003C\/strong\u003E: SIRP\u0026alpha;\u003Csup\u003Elow\u003C\/sup\u003E engineered macrophages immunotherapy for treatment of solid tumors.\u003Cbr \/\u003E\r\nPrincipal Investigators: Yuan Li, PhD, Georgia State University and Ned Waller, MD, PhD, FACP, Emory University\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E5.\u0026nbsp;\u003Cstrong\u003E\u003Ca href=\u0022https:\/\/industry.gatech.edu\/technology\/replaceable-heart-valve-prosthesis\u0022\u003EVerso Transcaval Docking Station\u003C\/a\u003E:\u003C\/strong\u003E a device that allows clinicians to precisely deliver and position existing transcatheter aortic or mitral valves in the IVC for treatment of Tricuspid Regurgitation.\u003Cbr \/\u003E\r\nPrincipal Investigator: Jorge Jimenez, PhD, Georgia Tech\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026ldquo;The applicants from this funding cycle were the most competitive we have seen since the relaunch of the Coulter program in 2014\u0026rdquo; says \u003Cstrong\u003EShawna Khouri\u003C\/strong\u003E, managing director of the Biolocity Program. \u0026ldquo;We are excited to work with our new awardees to support their technology development and hope to expand our outreach in the future to assist more teams working to positively impacting human health.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EFunding and project management provided by the Biolocity program is used to bridge the gap in development between early-stage university research and its path to the market. If you are interested in commercialization guidance for a device, therapeutic, or platform technology with the ability to positively impact human health, \u003Ca href=\u0022https:\/\/bit.ly\/biolocity_meeting\u0022\u003Eschedule a meeting here\u003C\/a\u003E.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003ETo learn more about Biolocity\u0026rsquo;s funding and partnership opportunities, visit \u003Ca href=\u0022http:\/\/www.Biolocity.org\u0022\u003Ewww.Biolocity.org\u003C\/a\u003E.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E###\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EBiolocity is a philanthropic, multi-institutional network supporting university medical technology commercialization in the southeast. Through a combination of investment, project management, consulting, and educational programming, Biolocity provides early-stage, patient impacting technologies with the resources needed to reach critical commercialization milestones.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Ca href=\u0022http:\/\/www.biolocity.org\/\u0022\u003Ehttp:\/\/www.Biolocity.org\u003C\/a\u003E\u0026nbsp;\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Ca href=\u0022mailto:Biolocity@gatech.edu\u0022\u003EBiolocity@gatech.edu\u003C\/a\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"Five promising biomedical research innovations across three campuses have been chosen for Biolocity\u2019s newest cohort"}],"uid":"27513","created_gmt":"2019-10-16 16:25:05","changed_gmt":"2019-10-29 14:41:50","author":"Walter Rich","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2019-10-16T00:00:00-04:00","iso_date":"2019-10-16T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"627653":{"id":"627653","type":"image","title":"Adam Marcus, Emory University: SaGA for Cancer Drug Discovery","body":null,"created":"1571242910","gmt_created":"2019-10-16 16:21:50","changed":"1571242910","gmt_changed":"2019-10-16 16:21:50","alt":"Adam Marcus, Emory University: SaGA for Cancer Drug Discovery","file":{"fid":"238977","name":"smAdam Marcus 0062501-19SN-0236.jpg","image_path":"\/sites\/default\/files\/images\/smAdam%20Marcus%200062501-19SN-0236.jpg","image_full_path":"http:\/\/hg.gatech.edu\/\/sites\/default\/files\/images\/smAdam%20Marcus%200062501-19SN-0236.jpg","mime":"image\/jpeg","size":201708,"path_740":"http:\/\/hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/smAdam%20Marcus%200062501-19SN-0236.jpg?itok=IE32pMxg"}},"627654":{"id":"627654","type":"image","title":"Ned Waller, Emory University: SIRPant Cellular Immunotherapy for Solid Tumors","body":null,"created":"1571242960","gmt_created":"2019-10-16 16:22:40","changed":"1571242960","gmt_changed":"2019-10-16 16:22:40","alt":"Ned Waller, Emory University: SIRPant Cellular Immunotherapy for Solid Tumors","file":{"fid":"238978","name":"sm-Waller head and torso July 2019.jpg","image_path":"\/sites\/default\/files\/images\/sm-Waller%20head%20and%20torso%20July%202019.jpg","image_full_path":"http:\/\/hg.gatech.edu\/\/sites\/default\/files\/images\/sm-Waller%20head%20and%20torso%20July%202019.jpg","mime":"image\/jpeg","size":169499,"path_740":"http:\/\/hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/sm-Waller%20head%20and%20torso%20July%202019.jpg?itok=xC-4P3zb"}},"627655":{"id":"627655","type":"image","title":"Peter Yunker, Georgia Tech: Heteroresistance AST","body":null,"created":"1571242989","gmt_created":"2019-10-16 16:23:09","changed":"1571242989","gmt_changed":"2019-10-16 16:23:09","alt":"Peter Yunker, Georgia Tech: Heteroresistance AST","file":{"fid":"238979","name":"Peter Yunker original (1).jpg","image_path":"\/sites\/default\/files\/images\/Peter%20Yunker%20original%20%281%29.jpg","image_full_path":"http:\/\/hg.gatech.edu\/\/sites\/default\/files\/images\/Peter%20Yunker%20original%20%281%29.jpg","mime":"image\/jpeg","size":4750443,"path_740":"http:\/\/hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/Peter%20Yunker%20original%20%281%29.jpg?itok=mL2HSSsQ"}}},"media_ids":["627653","627654","627655"],"groups":[{"id":"1254","name":"Wallace H. Coulter Dept. of Biomedical Engineering"}],"categories":[{"id":"138","name":"Biotechnology, Health, Bioengineering, Genetics"}],"keywords":[{"id":"1612","name":"BME"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003EWalter Rich\u003C\/p\u003E\r\n","format":"limited_html"}],"email":["wrich@gatech.edu"],"slides":[],"orientation":[],"userdata":""}}}